Elevation Oncology, Inc. (ELEV)

$1.02

-0.02 (-1.92%)
Rating:
Recommendation:
-
Symbol ELEV
Price $1.02
Beta 0.000
Volume Avg. 0.08M
Market Cap 23.767M
Shares () -
52 Week Range 0.723-5.2
1y Target Est -
DCF Unlevered ELEV DCF ->
DCF Levered ELEV LDCF ->
ROE -99.07% Strong Sell
ROA -96.94% Strong Sell
Operating Margin -
Debt / Equity 66.11% Buy
P/E 0.15 Neutral
P/B 0.35 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ELEV news


Dr. Shawn Leland Pharm.D., R.Ph.
Healthcare
Biotechnology
NASDAQ Global Select

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.